公开(公告)号：US20210269425A1

公开(公告)日：2021-09-02

申请号：US17235846

申请日：2021-04-20

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US20190135817A1

公开(公告)日：2019-05-09

申请号：US16251032

申请日：2019-01-17

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Ping Chen ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Mehran Jalaie ,  Asako Nagata ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Martha Alicia Ornelas ,  Cynthia Louise Palmer ,  Eugene Yuanjin Rui

IPC: C07D487/04 ,  C07D401/14 ,  C07D471/04

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2 , R2A , R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US10246433B2

公开(公告)日：2019-04-02

申请号：US15585880

申请日：2017-05-03

Applicant: Pfizer Inc.

Inventor： Martin Paul Edwards ,  Robert Arnold Kumpf ,  Pei-Pei Kung ,  Indrawan James McAlpine ,  Sacha Ninkovic ,  Eugene Yuanjin Rui ,  Scott Channing Sutton ,  John Howard Tatlock ,  Martin James Wythes ,  Luke Raymond Zehnder

IPC: C07D401/06 ,  C07D401/14 ,  C07D403/14 ,  C07D407/14 ,  C07D405/14 ,  C07D413/06 ,  C07D413/14 ,  C07D471/04 ,  C07D487/04

Abstract: This invention relates to compounds of general formula (I) in which R1, R2, U, V, L, M, R5, m, X, Y and Z are as defined herein, and the pharmaceutically acceptable salts thereof, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US10233188B2

公开(公告)日：2019-03-19

申请号：US15664265

申请日：2017-07-31

Applicant: Pfizer Inc.

Inventor： Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic

IPC: A61K31/519 ,  A61K31/4375 ,  A61K31/4545 ,  C07D487/04 ,  C07D401/12 ,  C07D401/14 ,  C07D471/04

Abstract: This invention relates to compounds of general Formula (I) and pharmaceutically acceptable salts thereof, in which R1, R2, R2A, R2B, R3, R4, R5A, R5B, R6, R7, R8, R9, p, q and r are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer.

公开(公告)号：US11220494B2

公开(公告)日：2022-01-11

申请号：US16942209

申请日：2020-07-29

Applicant: Pfizer Inc.

Inventor： Ping Chen ,  Sujin Cho-Schultz ,  Judith Gail Deal ,  Gary Michael Gallego ,  Mehran Jalaie ,  Robert Steven Kania ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Suvi Tuula Marjukka Orr ,  Cynthia Louise Palmer

IPC: C07D407/14 ,  C07D401/14 ,  C07D487/04 ,  C07D498/04

Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.

公开(公告)号：US11014911B2

公开(公告)日：2021-05-25

申请号：US16774786

申请日：2020-01-28

Applicant: Pfizer Inc.

Inventor： Douglas Carl Behenna ,  Kevin Daniel Freeman-Cook ,  Robert Louis Hoffman ,  Asako Nagata ,  Sacha Ninkovic ,  Scott Channing Sutton

IPC: C07D403/12 ,  A61P35/00 ,  C07D413/12

Abstract: This invention relates to compounds of Formula (I) and enantiomers thereof, and to pharmaceutically acceptable salts of Formula (I) and said enantiomers, wherein R1, R2 and R3 are as defined herein. The invention further relates to pharmaceutical compositions comprising such compounds and salts, and to methods and uses of such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject in need thereof.

公开(公告)号：US10766884B2

公开(公告)日：2020-09-08

申请号：US16391836

申请日：2019-04-23

Applicant: Pfizer Inc.

Inventor： Ping Chen ,  Sujin Cho-Schultz ,  Judith Gail Deal ,  Gary Michael Gallego ,  Mehran Jalaie ,  Robert Steven Kania ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Suvi Tuula Marjukka Orr ,  Cynthia Louise Palmer

IPC: C07D407/14 ,  C07D401/14 ,  C07D487/04 ,  C07D498/04

Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.

公开(公告)号：US20190330196A1

公开(公告)日：2019-10-31

申请号：US16391836

申请日：2019-04-23

Applicant: Pfizer Inc.

Inventor： Ping Chen ,  Sujin Cho-Schultz ,  Judith Gail Deal ,  Gary Michael Gallego ,  Mehran Jalaie ,  Robert Steven Kania ,  Sajiv Krishnan Nair ,  Sacha Ninkovic ,  Suvi Tuula Marjukka Orr ,  Cynthia Louise Palmer

IPC: C07D407/14 ,  C07D401/14 ,  C07D487/04 ,  C07D498/04

Abstract: This invention relates to compounds of Formula (I) or a pharmaceutically acceptable salt thereof, in which R-groups R1 to R23, A, Q, U, V, W, X, Y, Z, n, p and q are as defined herein, to pharmaceutical compositions comprising such compounds and salts, and to methods of using such compounds, salts and compositions for the treatment of abnormal cell growth, including cancer, in a subject.

公开(公告)号：US20180222862A1

公开(公告)日：2018-08-09

申请号：US15749963

申请日：2016-08-04

Applicant: Pfizer Inc. ,  iTeos Therapeutics

Inventor： Sacha Ninkovic ,  Michael Raymond Collins ,  Stefano Crosignani ,  Andreas Maderna ,  Indrawan James McAlpine ,  Stephanie Anne Scales ,  Martin Wythes

IPC: C07D209/18 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D409/12 ,  C07D413/12 ,  C07D405/12 ,  A61P25/16 ,  A61P25/24 ,  A61P25/28 ,  A61P3/04 ,  A61P31/18 ,  A61P35/02

CPC classification number: C07D209/18 ,  A61P3/04 ,  A61P25/16 ,  A61P25/24 ,  A61P25/28 ,  A61P31/18 ,  A61P35/02 ,  C07D209/10 ,  C07D401/12 ,  C07D401/14 ,  C07D403/10 ,  C07D403/12 ,  C07D403/14 ,  C07D405/12 ,  C07D407/12 ,  C07D409/12 ,  C07D413/12

Abstract: A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula I.

公开(公告)号：US09873690B2

公开(公告)日：2018-01-23

申请号：US15072534

申请日：2016-03-17

Applicant: Pfizer Inc. ,  iTeos Therapeutics

Inventor： Sacha Ninkovic ,  Stefano Crosignani ,  Indrawan James McAlpine ,  Michael Raymond Collins ,  Stephanie Anne Scales ,  Andreas Maderna ,  Martin Wythes

IPC: C07D417/04 ,  C07D417/14 ,  A61K31/404 ,  C07D417/12

CPC classification number: C07D417/04 ,  A61K31/404 ,  C07D417/12 ,  C07D417/14

Abstract: A compound of Formula I is provided: or pharmaceutically acceptable enantiomers, salts or solvates thereof. The invention further relates to the use of the compounds of Formula I as TDO2 inhibitors. The invention also relates to the use of the compounds of Formula I for the treatment and/or prevention of cancer, neurodegenerative disorders such as Parkinson's disease, Alzheimer's disease and Huntington's disease, chronic viral infections such as HCV and HIV, depression, and obesity. The invention also relates to a process for manufacturing compounds of Formula I.